Home > Riviste > La Rivista Italiana della Medicina di Laboratorio > Fascicoli precedenti > La Rivista Italiana della Medicina di Laboratorio 2022 Giugno;18(2) > La Rivista Italiana della Medicina di Laboratorio 2022 Giugno;18(2):73-6

ULTIMO FASCICOLO
 

JOURNAL TOOLS

Opzioni di pubblicazione
eTOC
Per abbonarsi
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

L’OSSERVATORIO   

La Rivista Italiana della Medicina di Laboratorio 2022 Giugno;18(2):73-6

DOI: 10.23736/S1825-859X.22.00142-6

Copyright © 2022 EDIZIONI MINERVA MEDICA

lingua: Inglese

PTX3: the ensemble biomarker of human diseases

Valeria PALUMBO 1, Rita BONFIGLIO 1, Vittorio MANZARI 2, Roberto BEI 2, Manuel SCIMECA 1, 3, 4

1 Department of Experimental Medicine, Tor Vergata University, Rome, Italy; 2 Department of Clinical Sciences and Translational Medicine, Tor Vergata University, Rome, Italy; 3 Vita-Salute San Raffaele University, Milan, Italy; 4 Faculty of Medicine, Saint Camillus International University of Health Sciences, Rome, Italy



The potential role of pentraxin 3 (PTX3) as a prognostic biomarker of several human diseases has been highlighted through several studies. In fact, PTX3 seems to take part in multiple processes underlying the development and progression of pathological conditions related to infections, cancer, cardiovascular dysfunction and bone metabolism, and reproductive function alterations. However, given the number and variability of processes in which PTX3 is involved, a deeper understanding of the biology of this molecule is required to candidate PTX3 as an ensemble biomarker for numerous human diseases.


KEY WORDS: Biomarkers; Laboratories; Prognosis

inizio pagina